<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd"><key id="d4" for="edge" attr.name="width" attr.type="long"/>
<key id="d3" for="edge" attr.name="title" attr.type="string"/>
<key id="d2" for="node" attr.name="size" attr.type="long"/>
<key id="d1" for="node" attr.name="color" attr.type="string"/>
<key id="d0" for="node" attr.name="group" attr.type="long"/>
<graph edgedefault="undirected"><node id="high doses">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease dementia (pdd)">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">3</data>
</node>
<node id="patients with parkinson's disease (pd)">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">4</data>
</node>
<node id="therapeutic effectiveness">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="chronic lung disease (cld) diagnosis">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="gba1 carriers">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">3</data>
</node>
<node id="phase ii trials">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="gaucher disease type 1 (gba1-pd)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="adverse events (aes)">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">13</data>
</node>
<node id="neurodegeneration">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">8</data>
</node>
<node id="high-dose">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="human subjects">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">2</data>
</node>
<node id="disease-specific treatment">
  <data key="d0">14</data>
  <data key="d1">#7c57db</data>
  <data key="d2">2</data>
</node>
<node id="usual dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="150 mg/day">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="combination medications">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="efficacy">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">5</data>
</node>
<node id="toxicology assessment">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="treatment">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">9</data>
</node>
<node id="enzyme replacement therapy (ert)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">14</data>
</node>
<node id="higher doses">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="gcase dysfunction">
  <data key="d0">9</data>
  <data key="d1">#57dbd5</data>
  <data key="d2">2</data>
</node>
<node id="dosing schedule">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="korean inds">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="british inds">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="in vitro testing">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="patient population">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">3</data>
</node>
<node id="risk of developing pd">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="severe mutations">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="Î±-synuclein triplication model">
  <data key="d0">21</data>
  <data key="d1">#57a7db</data>
  <data key="d2">4</data>
</node>
<node id="neurodegenerative pathology">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="4 mm concentration">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="cumulative incidence of parkinson's disease (pd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="gba gene mutation">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">27</data>
</node>
<node id="disease-modifying agent">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">2</data>
</node>
<node id="medical prescription">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="neonatal gaucher disease (ngd)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="safety profile">
  <data key="d0">4</data>
  <data key="d1">#c5db57</data>
  <data key="d2">5</data>
</node>
<node id="dementia">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="high-dose administration">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="cognitive dysfunction">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">3</data>
</node>
<node id="parkinson's disease (pd) brain">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="p.phe252ile">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="preclinical models">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="pharmacological chaperones">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">4</data>
</node>
<node id="alpha-synuclein">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">4</data>
</node>
<node id="ambroxol">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">98</data>
</node>
<node id="debilitating condition">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="combination therapy">
  <data key="d0">25</data>
  <data key="d1">#a7db57</data>
  <data key="d2">6</data>
</node>
<node id="therapeutic agent">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">4</data>
</node>
<node id="clinical practice">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">2</data>
</node>
<node id="glucocerebrosidase-specific pharmacological chaperone">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="parkinson's disease patients">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="glucocerebrosidase (gcase) activity">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">9</data>
</node>
<node id="treatment duration">
  <data key="d0">22</data>
  <data key="d1">#dbb757</data>
  <data key="d2">7</data>
</node>
<node id="neuronopathic gaucher disease">
  <data key="d0">18</data>
  <data key="d1">#576cdb</data>
  <data key="d2">7</data>
</node>
<node id="chronic lung disease (cld)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="patient-derived induced pluripotent stem cell line (ipsc)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="enzymatic activity">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="myoclonic epilepsy">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="comorbidities">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">3</data>
</node>
<node id="incidence rate">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="p.leu483pro">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="dementia with lewy bodies (dlb)">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">7</data>
</node>
<node id="p.val211phefs">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="carriers">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">3</data>
</node>
<node id="pharmacological agent">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="non-gba carriers">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="pharmacological chaperone">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">5</data>
</node>
<node id="neurodegenerative disease (ngd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="therapeutic indications">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic use">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="dementia with lewy bodies">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">4</data>
</node>
<node id="over-the-counter cough medication">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="mucus hypersecretion">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="long-term treatment">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">5</data>
</node>
<node id="therapeutic intervention">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">19</data>
</node>
<node id="eight patients">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="parkinson's disease (pd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">30</data>
</node>
<node id="idiopathic parkinson's disease brain">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">3</data>
</node>
<node id="disease-modifying pharmacological treatment">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="clinical trial">
  <data key="d0">5</data>
  <data key="d1">#9a57db</data>
  <data key="d2">48</data>
</node>
<node id="maximum dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="dramatic improvement">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="genome-wide association study (gwas)">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="therapeutic application">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="international trust">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="dosage">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">9</data>
</node>
<node id="disease-modifying therapies">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">4</data>
</node>
<node id="cough suppressant">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="approved dose range">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="affected patients">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">2</data>
</node>
<node id="idiopathic parkinson's disease (idiopathic pd)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="risk of developing">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="p.arg296gln">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="standard dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="gba1-related parkinson's disease">
  <data key="d0">10</data>
  <data key="d1">#b757db</data>
  <data key="d2">28</data>
</node>
<node id="clinical registries">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="neurodegenerative disease">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">8</data>
</node>
<node id="early intervention">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">2</data>
</node>
<node id="effectiveness">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="niemann-pick disease type c (ngd)">
  <data key="d0">24</data>
  <data key="d1">#dbd557</data>
  <data key="d2">4</data>
</node>
<node id="mutant gcase">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="availability">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="alpha-synuclein levels">
  <data key="d0">3</data>
  <data key="d1">#db576c</data>
  <data key="d2">5</data>
</node>
<node id="good responder">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="treating physician">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="population studies">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="non-gba1-related parkinson's disease">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="chronic respiratory disease">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">2</data>
</node>
<node id="pathogenesis of parkinson's disease">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">4</data>
</node>
<node id="variant form">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="patients">
  <data key="d0">11</data>
  <data key="d1">#d557db</data>
  <data key="d2">62</data>
</node>
<node id="korean national health insurance database (nhid)">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="chaperone-mediated autophagy (cma)">
  <data key="d0">1</data>
  <data key="d1">#57db5f</data>
  <data key="d2">3</data>
</node>
<node id="japanese inds">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="gaucher disease type 1 (gd1)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">7</data>
</node>
<node id="mild mutations">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="glucocerebrosidase (gcase)">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">12</data>
</node>
<node id="off-label applications">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="over-the-counter (otc) dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="australia">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="study participants">
  <data key="d0">6</data>
  <data key="d1">#57c5db</data>
  <data key="d2">8</data>
</node>
<node id="expectorant">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="pharmaceutical">
  <data key="d0">19</data>
  <data key="d1">#db578a</data>
  <data key="d2">10</data>
</node>
<node id="further research">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="gaucher disease (gd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">19</data>
</node>
<node id="current clinical trials">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="risk of parkinson's disease (pd)">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">5</data>
</node>
<node id="global markets">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="respiratory disorders">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="early onset">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="pathological deposition">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">1</data>
</node>
<node id="nonusers">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">2</data>
</node>
<node id="parkinson's disease">
  <data key="d0">16</data>
  <data key="d1">#db7c57</data>
  <data key="d2">33</data>
</node>
<node id="over-the-counter (otc) medication">
  <data key="d0">15</data>
  <data key="d1">#8adb57</data>
  <data key="d2">4</data>
</node>
<node id="recommended dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">2</data>
</node>
<node id="gcase activity">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">20</data>
</node>
<node id="12,580 patients">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">1</data>
</node>
<node id="gba-associated parkinson's disease (gba-pd)">
  <data key="d0">7</data>
  <data key="d1">#db9a57</data>
  <data key="d2">15</data>
</node>
<node id="mutation carriers">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="pharmaceutical compound">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">10</data>
</node>
<node id="chronic liver disease (cld) patients">
  <data key="d0">13</data>
  <data key="d1">#db57a7</data>
  <data key="d2">7</data>
</node>
<node id="p.asn227ser">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<node id="mucolytic agent">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">3</data>
</node>
<node id="cost-effectiveness">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="repurposed pharmaceutical">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="5 mm concentration">
  <data key="d0">2</data>
  <data key="d1">#5f57db</data>
  <data key="d2">2</data>
</node>
<node id="new england journal of medicine">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="standard dose">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="mean dosage">
  <data key="d0">12</data>
  <data key="d1">#578adb</data>
  <data key="d2">1</data>
</node>
<node id="genetic risk factor">
  <data key="d0">8</data>
  <data key="d1">#57db9a</data>
  <data key="d2">1</data>
</node>
<edge source="high doses" target="ambroxol">
  <data key="d3">is administered at</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease dementia (pdd)" target="gba gene mutation">
  <data key="d3">increase risk of developing</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease dementia (pdd)" target="parkinson's disease (pd)">
  <data key="d3">can progress to</data>
  <data key="d4">1</data>
</edge>
<edge source="patients with parkinson's disease (pd)" target="gba gene mutation">
  <data key="d3">carry</data>
  <data key="d4">1</data>
</edge>
<edge source="therapeutic effectiveness" target="ambroxol">
  <data key="d3">may vary based on</data>
  <data key="d4">1</data>
</edge>
<edge source="chronic lung disease (cld) diagnosis" target="ambroxol">
  <data key="d3">prescribed after</data>
  <data key="d4">1</data>
</edge>
<edge source="gba1 carriers" target="parkinson's disease (pd)">
  <data key="d3">are associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="phase ii trials" target="parkinson's disease (pd)">
  <data key="d3">studies effects in</data>
  <data key="d4">1</data>
</edge>
<edge source="gaucher disease type 1 (gba1-pd)" target="ambroxol">
  <data key="d3">is used for</data>
  <data key="d4">1</data>
</edge>
<edge source="adverse events (aes)" target="ambroxol">
  <data key="d3">is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="neurodegeneration" target="parkinson's disease (pd)">
  <data key="d3">leads to</data>
  <data key="d4">1</data>
</edge>
<edge source="neurodegeneration" target="parkinson's disease">
  <data key="d3">is a process in</data>
  <data key="d4">1</data>
</edge>
<edge source="neurodegeneration" target="gba1-related parkinson's disease">
  <data key="d3">contributes to the development of</data>
  <data key="d4">1</data>
</edge>
<edge source="high-dose" target="ambroxol">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="human subjects" target="clinical trial">
  <data key="d3">involve</data>
  <data key="d4">1</data>
</edge>
<edge source="human subjects" target="ambroxol">
  <data key="d3">is administered to</data>
  <data key="d4">1</data>
</edge>
<edge source="disease-specific treatment" target="ambroxol">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="usual dosage" target="ambroxol">
  <data key="d3">is a standard measurement of</data>
  <data key="d4">1</data>
</edge>
<edge source="150 mg/day" target="ambroxol">
  <data key="d3">is the dosage of</data>
  <data key="d4">1</data>
</edge>
<edge source="150 mg/day" target="standard dosage">
  <data key="d3">is typical for</data>
  <data key="d4">1</data>
</edge>
<edge source="combination medications" target="parkinson's disease (pd)">
  <data key="d3">used in combination for</data>
  <data key="d4">1</data>
</edge>
<edge source="efficacy" target="ambroxol">
  <data key="d3">is related to</data>
  <data key="d4">1</data>
</edge>
<edge source="efficacy" target="therapeutic intervention">
  <data key="d3">is a characteristic of</data>
  <data key="d4">1</data>
</edge>
<edge source="toxicology assessment" target="ambroxol">
  <data key="d3">is required for</data>
  <data key="d4">1</data>
</edge>
<edge source="treatment" target="parkinson's disease (pd)">
  <data key="d3">requires a</data>
  <data key="d4">1</data>
</edge>
<edge source="treatment" target="patients">
  <data key="d3">seek</data>
  <data key="d4">1</data>
</edge>
<edge source="treatment" target="ambroxol">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="treatment" target="gaucher disease (gd)">
  <data key="d3">requires a</data>
  <data key="d4">1</data>
</edge>
<edge source="treatment" target="therapeutic intervention">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="patients">
  <data key="d3">are untreated with,are treated with,received</data>
  <data key="d4">1</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="ambroxol">
  <data key="d3">is studied for safety</data>
  <data key="d4">1</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="long-term treatment">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="treatment duration">
  <data key="d3">has duration</data>
  <data key="d4">1</data>
</edge>
<edge source="enzyme replacement therapy (ert)" target="gaucher disease type 1 (gd1)">
  <data key="d3">is a treatment for</data>
  <data key="d4">1</data>
</edge>
<edge source="higher doses" target="ambroxol">
  <data key="d3">is administered in</data>
  <data key="d4">1</data>
</edge>
<edge source="gcase dysfunction" target="gba gene mutation">
  <data key="d3">is caused by</data>
  <data key="d4">1</data>
</edge>
<edge source="dosing schedule" target="ambroxol">
  <data key="d3">is part of</data>
  <data key="d4">1</data>
</edge>
<edge source="korean inds" target="ambroxol">
  <data key="d3">tested for efficacy on</data>
  <data key="d4">1</data>
</edge>
<edge source="british inds" target="ambroxol">
  <data key="d3">tested for efficacy on</data>
  <data key="d4">1</data>
</edge>
<edge source="in vitro testing" target="ambroxol">
  <data key="d3">skips</data>
  <data key="d4">1</data>
</edge>
<edge source="patient population" target="parkinson's disease (pd)">
  <data key="d3">is diagnosed in</data>
  <data key="d4">1</data>
</edge>
<edge source="risk of developing pd" target="gba gene mutation">
  <data key="d3">increases the</data>
  <data key="d4">1</data>
</edge>
<edge source="severe mutations" target="gba gene mutation">
  <data key="d3">classified as</data>
  <data key="d4">1</data>
</edge>
<edge source="severe mutations" target="gcase activity">
  <data key="d3">determines</data>
  <data key="d4">1</data>
</edge>
<edge source="Î±-synuclein triplication model" target="parkinson's disease (pd)">
  <data key="d3">is related to</data>
  <data key="d4">1</data>
</edge>
<edge source="neurodegenerative pathology" target="alpha-synuclein">
  <data key="d3">is not observed in</data>
  <data key="d4">1</data>
</edge>
<edge source="4 mm concentration" target="gcase activity">
  <data key="d3">may increase</data>
  <data key="d4">1</data>
</edge>
<edge source="4 mm concentration" target="ambroxol">
  <data key="d3">is at concentration</data>
  <data key="d4">1</data>
</edge>
<edge source="cumulative incidence of parkinson's disease (pd)" target="parkinson's disease (pd)">
  <data key="d3">is higher in</data>
  <data key="d4">1</data>
</edge>
<edge source="cumulative incidence of parkinson's disease (pd)" target="ambroxol">
  <data key="d3">is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="dementia with lewy bodies">
  <data key="d3">increase risk of developing</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="dementia with lewy bodies (dlb)">
  <data key="d3">are more prevalent in</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease (pd)">
  <data key="d3">increase risk of</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="genome-wide association study (gwas)">
  <data key="d3">confirms correlation with</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="enzymatic activity">
  <data key="d3">affects</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease (pd) brain">
  <data key="d3">is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="pathogenesis of parkinson's disease">
  <data key="d3">suggests a link to</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="idiopathic parkinson's disease brain">
  <data key="d3">may lack</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="parkinson's disease patients">
  <data key="d3">present in percentage of</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="population studies">
  <data key="d3">demonstrate higher incidence of</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="p.arg296gln">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="p.asn227ser">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="p.leu483pro">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="p.phe252ile">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="p.val211phefs">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="glucocerebrosidase (gcase)">
  <data key="d3">is affected by</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="affected patients">
  <data key="d3">affects</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="patients">
  <data key="d3">carrying</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="gaucher disease (gd)">
  <data key="d3">cause</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="genetic risk factor">
  <data key="d3">are a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="mutation carriers">
  <data key="d3">are associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="gba gene mutation" target="mild mutations">
  <data key="d3">classified as</data>
  <data key="d4">1</data>
</edge>
<edge source="disease-modifying agent" target="ambroxol">
  <data key="d3">is suggested to be a</data>
  <data key="d4">1</data>
</edge>
<edge source="medical prescription" target="ambroxol">
  <data key="d3">does not require</data>
  <data key="d4">1</data>
</edge>
<edge source="neonatal gaucher disease (ngd)" target="ambroxol">
  <data key="d3">is used for treatment in</data>
  <data key="d4">1</data>
</edge>
<edge source="safety profile" target="ambroxol">
  <data key="d3">has</data>
  <data key="d4">1</data>
</edge>
<edge source="dementia" target="dementia with lewy bodies (dlb)">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="dementia" target="ambroxol">
  <data key="d3">is used in treatment for</data>
  <data key="d4">1</data>
</edge>
<edge source="high-dose administration" target="ambroxol">
  <data key="d3">is administered in</data>
  <data key="d4">1</data>
</edge>
<edge source="cognitive dysfunction" target="dementia with lewy bodies">
  <data key="d3">is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd) brain" target="enzymatic activity">
  <data key="d3">has decreased</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd) brain" target="idiopathic parkinson's disease brain">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd) brain" target="pathogenesis of parkinson's disease">
  <data key="d3">is influenced by</data>
  <data key="d4">1</data>
</edge>
<edge source="preclinical models" target="parkinson's disease (pd)">
  <data key="d3">of</data>
  <data key="d4">1</data>
</edge>
<edge source="pharmacological chaperones" target="ambroxol">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="pharmacological chaperones" target="gba1-related parkinson's disease">
  <data key="d3">are used to treat</data>
  <data key="d4">1</data>
</edge>
<edge source="alpha-synuclein" target="dementia with lewy bodies">
  <data key="d3">is characterized by</data>
  <data key="d4">1</data>
</edge>
<edge source="alpha-synuclein" target="pathological deposition">
  <data key="d3">causes</data>
  <data key="d4">1</data>
</edge>
<edge source="alpha-synuclein" target="chaperone-mediated autophagy (cma)">
  <data key="d3">may reduce</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="gcase activity">
  <data key="d3">is affected by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="parkinson's disease (pd)">
  <data key="d3">is used for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="patients">
  <data key="d3">use,are treated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="glucocerebrosidase (gcase) activity">
  <data key="d3">increases</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="clinical trial">
  <data key="d3">are not needed for,evaluate,are ongoing for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="study participants">
  <data key="d3">took</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="dosage">
  <data key="d3">is measured in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="5 mm concentration">
  <data key="d3">is at concentration</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="alpha-synuclein levels">
  <data key="d3">decreases</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="chronic lung disease (cld)">
  <data key="d3">is relevant to</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="chronic respiratory disease">
  <data key="d3">is treated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="effectiveness">
  <data key="d3">is questioned</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="expectorant">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="nonusers">
  <data key="d3">compared to</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="parkinson's disease">
  <data key="d3">is associated with risk of,is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="risk of parkinson's disease (pd)">
  <data key="d3">is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="pharmaceutical">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="recommended dosage">
  <data key="d3">is prescribed at</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="standard dosage">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="standard dose">
  <data key="d3">does not produce</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="therapeutic agent">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="therapeutic application">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="approved dose range">
  <data key="d3">is the range within which Ambroxol is administered</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="chronic liver disease (cld) patients">
  <data key="d3">prescribed to</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="clinical practice">
  <data key="d3">involves</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="korean national health insurance database (nhid)">
  <data key="d3">is used to investigate</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="neuronopathic gaucher disease">
  <data key="d3">is suggested as an augmentative pharmacological agent for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="pharmacological agent">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="availability">
  <data key="d3">is widely</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="cost-effectiveness">
  <data key="d3">is relatively</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="dramatic improvement">
  <data key="d3">causes</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="gaucher disease (gd)">
  <data key="d3">is used for treating</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="gaucher disease type 1 (gd1)">
  <data key="d3">is used in treatment for,is used for treatment in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">is used for treatment in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="global markets">
  <data key="d3">faces barriers in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="maximum dosage">
  <data key="d3">has a specified</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="niemann-pick disease type c (ngd)">
  <data key="d3">is treated by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="non-gba carriers">
  <data key="d3">is used in treatment for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="off-label applications">
  <data key="d3">considered for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="over-the-counter (otc) dosage">
  <data key="d3">is administered at</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="over-the-counter (otc) medication">
  <data key="d3">are related to</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="over-the-counter cough medication">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="pharmacological chaperone">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="therapeutic intervention">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="therapeutic use">
  <data key="d3">is associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="treating physician">
  <data key="d3">is prescribed by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="clinical registries">
  <data key="d3">disallowed entry of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="eight patients">
  <data key="d3">stopped taking</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="good responder">
  <data key="d3">is treated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="japanese inds">
  <data key="d3">tested for efficacy on</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="mutant gcase">
  <data key="d3">is targeted by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="myoclonic epilepsy">
  <data key="d3">is ameliorated by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="treatment duration">
  <data key="d3">is measured in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="mucolytic agent">
  <data key="d3">is</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="mucus hypersecretion">
  <data key="d3">associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="pharmaceutical compound">
  <data key="d3">is</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="respiratory disorders">
  <data key="d3">treats</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="australia">
  <data key="d3">tested in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="cough suppressant">
  <data key="d3">is classified as</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="gba1-related parkinson's disease">
  <data key="d3">is treated by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="glucocerebrosidase-specific pharmacological chaperone">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="international trust">
  <data key="d3">aims to upgrade</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="mean dosage">
  <data key="d3">has a</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="neurodegenerative disease (ngd)">
  <data key="d3">is used for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="non-gba1-related parkinson's disease">
  <data key="d3">hypothesized to be effective in</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="repurposed pharmaceutical">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="therapeutic indications">
  <data key="d3">is used for</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="current clinical trials">
  <data key="d3">involve</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="idiopathic parkinson's disease (idiopathic pd)">
  <data key="d3">is treated by</data>
  <data key="d4">1</data>
</edge>
<edge source="ambroxol" target="new england journal of medicine">
  <data key="d3">does not mention</data>
  <data key="d4">1</data>
</edge>
<edge source="debilitating condition" target="parkinson's disease (pd)">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="combination therapy" target="parkinson's disease (pd)">
  <data key="d3">is applicable to</data>
  <data key="d4">1</data>
</edge>
<edge source="clinical practice" target="dosage">
  <data key="d3">is permitted in</data>
  <data key="d4">1</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="alpha-synuclein levels">
  <data key="d3">are affected by</data>
  <data key="d4">1</data>
</edge>
<edge source="glucocerebrosidase (gcase) activity" target="therapeutic intervention">
  <data key="d3">should aim to correct</data>
  <data key="d4">1</data>
</edge>
<edge source="treatment duration" target="patients">
  <data key="d3">undergo</data>
  <data key="d4">1</data>
</edge>
<edge source="neuronopathic gaucher disease" target="therapeutic intervention">
  <data key="d3">requires</data>
  <data key="d4">1</data>
</edge>
<edge source="neuronopathic gaucher disease" target="gba1-related parkinson's disease">
  <data key="d3">is a disease associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="chronic lung disease (cld)" target="parkinson's disease">
  <data key="d3">risk factor for</data>
  <data key="d4">1</data>
</edge>
<edge source="chronic lung disease (cld)" target="korean national health insurance database (nhid)">
  <data key="d3">contains data on</data>
  <data key="d4">1</data>
</edge>
<edge source="patient-derived induced pluripotent stem cell line (ipsc)" target="parkinson's disease (pd)">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="enzymatic activity" target="pathogenesis of parkinson's disease">
  <data key="d3">is closely associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="enzymatic activity" target="glucocerebrosidase (gcase)">
  <data key="d3">is reduced in</data>
  <data key="d4">1</data>
</edge>
<edge source="comorbidities" target="parkinson's disease (pd)">
  <data key="d3">requires control for</data>
  <data key="d4">1</data>
</edge>
<edge source="incidence rate" target="parkinson's disease (pd)">
  <data key="d3">is a measure of</data>
  <data key="d4">1</data>
</edge>
<edge source="dementia with lewy bodies (dlb)" target="patients">
  <data key="d3">have</data>
  <data key="d4">1</data>
</edge>
<edge source="carriers" target="parkinson's disease (pd)">
  <data key="d3">are associated with</data>
  <data key="d4">1</data>
</edge>
<edge source="carriers" target="patients">
  <data key="d3">are different from</data>
  <data key="d4">1</data>
</edge>
<edge source="carriers" target="gaucher disease (gd)">
  <data key="d3">can have</data>
  <data key="d4">1</data>
</edge>
<edge source="pharmacological chaperone" target="gba1-related parkinson's disease">
  <data key="d3">is a condition treated by</data>
  <data key="d4">1</data>
</edge>
<edge source="neurodegenerative disease (ngd)" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">are conditions related to</data>
  <data key="d4">1</data>
</edge>
<edge source="dementia with lewy bodies" target="disease-modifying pharmacological treatment">
  <data key="d3">has no available</data>
  <data key="d4">1</data>
</edge>
<edge source="long-term treatment" target="parkinson's disease (pd)">
  <data key="d3">requires</data>
  <data key="d4">1</data>
</edge>
<edge source="long-term treatment" target="gaucher disease (gd)">
  <data key="d3">requires</data>
  <data key="d4">1</data>
</edge>
<edge source="therapeutic intervention" target="parkinson's disease (pd)">
  <data key="d3">is a viable treatment for</data>
  <data key="d4">1</data>
</edge>
<edge source="therapeutic intervention" target="patients">
  <data key="d3">provides for</data>
  <data key="d4">1</data>
</edge>
<edge source="therapeutic intervention" target="parkinson's disease">
  <data key="d3">is for</data>
  <data key="d4">1</data>
</edge>
<edge source="therapeutic intervention" target="gaucher disease (gd)">
  <data key="d3">is a viable treatment for</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="risk of developing">
  <data key="d3">is higher for carriers of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="further research">
  <data key="d3">need more investigation of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="gaucher disease type 1 (gd1)">
  <data key="d3">diagnosed with</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="disease-modifying therapies">
  <data key="d3">are aimed at</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="neurodegenerative disease">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="12,580 patients">
  <data key="d3">is the sample size of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="early intervention">
  <data key="d3">may prevent or delay onset of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="early onset">
  <data key="d3">is characteristic of</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="gaucher disease (gd)">
  <data key="d3">are conditions addressed by</data>
  <data key="d4">1</data>
</edge>
<edge source="parkinson's disease (pd)" target="variant form">
  <data key="d3">is a form of</data>
  <data key="d4">1</data>
</edge>
<edge source="idiopathic parkinson's disease brain" target="pathogenesis of parkinson's disease">
  <data key="d3">is relevant to</data>
  <data key="d4">1</data>
</edge>
<edge source="clinical trial" target="patients">
  <data key="d3">participated in</data>
  <data key="d4">1</data>
</edge>
<edge source="clinical trial" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="clinical trial" target="parkinson's disease">
  <data key="d3">is related to</data>
  <data key="d4">1</data>
</edge>
<edge source="clinical trial" target="gba1-related parkinson's disease">
  <data key="d3">conducts research on</data>
  <data key="d4">1</data>
</edge>
<edge source="disease-modifying therapies" target="parkinson's disease">
  <data key="d3">target</data>
  <data key="d4">1</data>
</edge>
<edge source="disease-modifying therapies" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">awaits approval for</data>
  <data key="d4">1</data>
</edge>
<edge source="neurodegenerative disease" target="parkinson's disease">
  <data key="d3">is a type of</data>
  <data key="d4">1</data>
</edge>
<edge source="chronic respiratory disease" target="parkinson's disease">
  <data key="d3">can co-occur with</data>
  <data key="d4">1</data>
</edge>
<edge source="patients" target="chronic liver disease (cld) patients">
  <data key="d3">involves</data>
  <data key="d4">1</data>
</edge>
<edge source="patients" target="gaucher disease type 1 (gd1)">
  <data key="d3">affects</data>
  <data key="d4">1</data>
</edge>
<edge source="patients" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">includes</data>
  <data key="d4">1</data>
</edge>
<edge source="patients" target="gaucher disease (gd)">
  <data key="d3">can have</data>
  <data key="d4">1</data>
</edge>
<edge source="gaucher disease type 1 (gd1)" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">received ambroxol as single therapy</data>
  <data key="d4">1</data>
</edge>
<edge source="mild mutations" target="gcase activity">
  <data key="d3">determines</data>
  <data key="d4">1</data>
</edge>
<edge source="glucocerebrosidase (gcase)" target="parkinson's disease">
  <data key="d3">is implicated in</data>
  <data key="d4">1</data>
</edge>
<edge source="gaucher disease (gd)" target="gba-associated parkinson's disease (gba-pd)">
  <data key="d3">is related to</data>
  <data key="d4">1</data>
</edge>
<edge source="gaucher disease (gd)" target="pharmaceutical compound">
  <data key="d3">is developed for</data>
  <data key="d4">1</data>
</edge>
<edge source="risk of parkinson's disease (pd)" target="chronic liver disease (cld) patients">
  <data key="d3">is higher in</data>
  <data key="d4">1</data>
</edge>
<edge source="gcase activity" target="5 mm concentration">
  <data key="d3">does not increase</data>
  <data key="d4">1</data>
</edge>
</graph></graphml>